Key result
Early beta-blocker administration in STEMI patients with risk factors for shock was not associated with cardiogenic shock development.
Why the study?
Beta-blockers are recommended within 24 hours of STEMI except in patients at risk of cardiogenic shock, but whether early use is associated with shock development in this population remained unclear.
Does early beta-blocker administration increase the risk of cardiogenic shock in STEMI patients with risk factors for shock?
Cohort (n=216)
Does early beta-blocker administration increase the risk of cardiogenic shock in STEMI patients with risk factors for shock?
Early beta-blocker administration in STEMI patients with risk factors for cardiogenic shock was not significantly associated with shock development, suggesting potential safety in this high-risk population.
Answers are grounded in this paper and cite their sources.
Early beta-blocker use was not associated with shock in high-risk STEMI; leaves open need for prospective trials before practice change.
Beta-blockers are recommended in the first 24 hours after ST-segment elevation myocardial infarction (STEMI) except in those at risk of cardiogenic shock. This retrospective cohort study aimed to assess if early beta-blocker use was associated with cardiogenic shock development in STEMI patients. Cardiogenic shock was assessed in adult patients with STEMI undergoing percutaneous coronary intervention (PCI) with guideline defined risk factors for shock (age above 70 years, systolic blood pressure below 120 mmHg, and heart rate above 120 bpm or below 60 bpm) who did or did not receive a beta-blocker within 24 hours of PCI. Multivariable logistic regression was used to assess the association between cardiogenic shock development and early beta-blocker administration. A total of 216 patients were included, 85 with early beta-blocker administration and 131 without. Patients who received an early beta-blocker versus those who did not had a median (interquartile range) age of 63 (52-71) versus 66 (54-76; P = .2260) and peak troponin of 58.3 (15.0-132.4) ng/mL versus 51.6 (16.6-139.5; P = .9884). Cardiogenic shock occurred in 4.7% (n = 4) patients with early beta-blocker use versus 12.2% (n = 16; P = .0909) without. After backward stepwise logistic regression, early beta-blocker use was not associated with cardiogenic shock (adjusted odd ratio [aOR] 0.334, 95% confidence interval (CI) 0.106-1.047; P = .0599), but those with a peak troponin over 56 ng/mL had an over three-fold increased risk of developing cardiogenic shock (aOR 3.434, 95% CI 1.191-9.902; P = .0224) regardless of beta blocker administration. Early beta-blocker administration in STEMI patients may not be associated with shock development.
No takes yet. Share an insight, caveat, or question.
Castoro et al. (2024) conducted a cohort in ST-segment elevation myocardial infarction (STEMI) with risk factors for cardiogenic shock (n=216). Early beta-blocker administration vs. No early beta-blocker administration was evaluated on Cardiogenic shock development (aOR 0.334, 95% CI 0.106-1.047, p=.0599). Early beta-blocker administration in STEMI patients with risk factors for shock was not associated with cardiogenic shock development.
Synapse has enriched 10 related papers. Consider them for comparative context: